GYPB

Across TCGA pan-cancer cohorts, GYPB Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GYPB data layer compared with 12 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher GYPB Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GYPB expression acts as an unfavorable survival marker.

COAD, SKCM, and UCEC are the cancer types where GYPB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.175	0.692	<.001	45	view →
SKCM	DFS	Median	All	0.087	0.757	<.001	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GYPB–COAD (DFS)

Open the COAD breakdown →